received a $2.2 million investment. The financing
was led by GO Capital Fund and BDC Venture Capital. Epicentre Technologies and Alethia founders, Yves Cornellier and Mario Filion, also participated.
“These funds represent the first step toward the closing of a presently evolving Series A round that will help bring our lead therapeutics into the clinic,” remarks Cornellier, president and CEO. Alethia's mAb programs are focused in three indications.
The company's most advanced mAb targets a secreted factor called clusterin, which plays a role in tumor progression and invasion. AB-0447 is being developed against an antigen that reportedly is over-expressed in more than 90% of ovarian tumors.
The firm’s severe bone loss program targets AB-0440, a cell surface protein that is stimulated during early osteoclast differentiation. Lead candidates in this program are currently under evaluation for animal studies.